#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	ana	2-1

#Text=This is one of the first mixed methods studies to assess the “ care cascade ” and to explore the challenges associated with the implementation of ACF for TB in India .
2-1	14-18	This	abstract	giv	_	_
2-2	19-21	is	_	_	_	_
2-3	22-25	one	abstract[3]	new[3]	_	_
2-4	26-28	of	abstract[3]	new[3]	_	_
2-5	29-32	the	abstract[3]|event[5]	new[3]|new[5]	coref	11-14[73_5]
2-6	33-38	first	abstract[3]|event[5]	new[3]|new[5]	_	_
2-7	39-44	mixed	abstract[3]|event[5]	new[3]|new[5]	_	_
2-8	45-52	methods	abstract[3]|abstract|event[5]	new[3]|new|new[5]	_	_
2-9	53-60	studies	abstract[3]|event[5]	new[3]|new[5]	_	_
2-10	61-63	to	_	_	_	_
2-11	64-70	assess	_	_	_	_
2-12	71-74	the	abstract[7]	new[7]	_	_
2-13	75-76	“	abstract[7]	new[7]	_	_
2-14	77-81	care	abstract|abstract[7]	new|new[7]	coref	9-21[59_0]
2-15	82-89	cascade	abstract[7]	new[7]	_	_
2-16	90-91	”	abstract[7]	new[7]	_	_
2-17	92-95	and	_	_	_	_
2-18	96-98	to	_	_	_	_
2-19	99-106	explore	_	_	_	_
2-20	107-110	the	abstract[8]	new[8]	_	_
2-21	111-121	challenges	abstract[8]	new[8]	_	_
2-22	122-132	associated	_	_	_	_
2-23	133-137	with	_	_	_	_
2-24	138-141	the	abstract[9]	new[9]	_	_
2-25	142-156	implementation	abstract[9]	new[9]	_	_
2-26	157-159	of	abstract[9]	new[9]	_	_
2-27	160-163	ACF	abstract[9]|abstract	new[9]|new	coref	4-4
2-28	164-167	for	abstract[9]	new[9]	_	_
2-29	168-170	TB	abstract[9]|abstract[11]	new[9]|new[11]	coref	4-31[0_11]
2-30	171-173	in	abstract[9]|abstract[11]	new[9]|new[11]	_	_
2-31	174-179	India	abstract[9]|abstract[11]|place	new[9]|new[11]|new	_	_
2-32	180-181	.	_	_	_	_

#Text=Our study has a few key findings .
3-1	182-185	Our	person|abstract[14]	acc|new[14]	ana|coref|ana|coref	10-1|10-5[0_14]|10-1|10-5[0_14]
3-2	186-191	study	abstract[14]	new[14]	_	_
3-3	192-195	has	_	_	_	_
3-4	196-197	a	abstract[15]	new[15]	coref	10-4[68_15]
3-5	198-201	few	abstract[15]	new[15]	_	_
3-6	202-205	key	abstract[15]	new[15]	_	_
3-7	206-214	findings	abstract[15]	new[15]	_	_
3-8	215-216	.	_	_	_	_

#Text=First , the ACF activity had a low PTBP detection rate with only three out of 1000 apparently healthy individuals enumerated during house-to-house visits having symptoms that were suggestive of TB .
4-1	217-222	First	_	_	_	_
4-2	223-224	,	_	_	_	_
4-3	225-228	the	abstract[17]	new[17]	coref	13-2[82_17]
4-4	229-232	ACF	place|abstract[17]	giv|new[17]	coref	11-18
4-5	233-241	activity	abstract[17]	new[17]	_	_
4-6	242-245	had	_	_	_	_
4-7	246-247	a	abstract[19]	new[19]	coref	6-11[33_19]
4-8	248-251	low	abstract[19]	new[19]	_	_
4-9	252-256	PTBP	abstract[19]	new[19]	_	_
4-10	257-266	detection	abstract|abstract[19]	new|new[19]	coref	11-10[72_0]
4-11	267-271	rate	abstract[19]	new[19]	_	_
4-12	272-276	with	abstract[19]	new[19]	_	_
4-13	277-281	only	abstract[19]	new[19]	_	_
4-14	282-287	three	abstract[19]	new[19]	_	_
4-15	288-291	out	_	_	_	_
4-16	292-294	of	_	_	_	_
4-17	295-299	1000	person[20]	new[20]	coref	13-14[0_20]
4-18	300-310	apparently	person[20]	new[20]	_	_
4-19	311-318	healthy	person[20]	new[20]	_	_
4-20	319-330	individuals	person[20]	new[20]	_	_
4-21	331-341	enumerated	_	_	_	_
4-22	342-348	during	_	_	_	_
4-23	349-363	house-to-house	abstract[21]	new[21]	coref	20-8[129_21]
4-24	364-370	visits	abstract[21]	new[21]	_	_
4-25	371-377	having	_	_	_	_
4-26	378-386	symptoms	abstract	new	coref	12-8
4-27	387-391	that	_	_	_	_
4-28	392-396	were	_	_	_	_
4-29	397-407	suggestive	_	_	_	_
4-30	408-410	of	_	_	_	_
4-31	411-413	TB	abstract	giv	coref	6-27
4-32	414-415	.	_	_	_	_

#Text=Second , there was high attrition of PTBP prior to diagnosis with only two out of three PTBP who were referred actually visiting the health facility .
5-1	416-422	Second	_	_	_	_
5-2	423-424	,	_	_	_	_
5-3	425-430	there	_	_	_	_
5-4	431-434	was	_	_	_	_
5-5	435-439	high	event[24]	new[24]	coref	18-7[0_24]
5-6	440-449	attrition	event[24]	new[24]	_	_
5-7	450-452	of	event[24]	new[24]	_	_
5-8	453-457	PTBP	event[24]|abstract[25]	new[24]|new[25]	coref	11-10[0_25]
5-9	458-463	prior	event[24]|abstract[25]	new[24]|new[25]	_	_
5-10	464-466	to	event[24]	new[24]	_	_
5-11	467-476	diagnosis	event[24]|event[26]	new[24]|new[26]	coref	9-8[55_26]
5-12	477-481	with	event[24]|event[26]	new[24]|new[26]	_	_
5-13	482-486	only	event[24]|event[26]|quantity[27]	new[24]|new[26]|new[27]	_	_
5-14	487-490	two	event[24]|event[26]|quantity[27]	new[24]|new[26]|new[27]	_	_
5-15	491-494	out	event[24]	new[24]	_	_
5-16	495-497	of	event[24]	new[24]	_	_
5-17	498-503	three	event[24]|person[28]	new[24]|new[28]	coref	16-16[0_28]
5-18	504-508	PTBP	event[24]|person[28]	new[24]|new[28]	_	_
5-19	509-512	who	_	_	_	_
5-20	513-517	were	_	_	_	_
5-21	518-526	referred	_	_	_	_
5-22	527-535	actually	_	_	_	_
5-23	536-544	visiting	_	_	_	_
5-24	545-548	the	place[29]	new[29]	coref	9-33[64_29]
5-25	549-555	health	place[29]	new[29]	_	_
5-26	556-564	facility	place[29]	new[29]	_	_
5-27	565-566	.	_	_	_	_

#Text=Third , among PTBPs who undergo the diagnostic test , the sputum positivity rate was high , with one out of four having been diagnosed with TB .
6-1	567-572	Third	_	_	_	_
6-2	573-574	,	_	_	_	_
6-3	575-580	among	_	_	_	_
6-4	581-586	PTBPs	person	new	coref	8-34[51_0]
6-5	587-590	who	_	_	_	_
6-6	591-598	undergo	_	_	_	_
6-7	599-602	the	abstract[31]	new[31]	_	_
6-8	603-613	diagnostic	abstract[31]	new[31]	_	_
6-9	614-618	test	abstract[31]	new[31]	_	_
6-10	619-620	,	_	_	_	_
6-11	621-624	the	abstract[33]	giv[33]	coref	11-6[70_33]
6-12	625-631	sputum	abstract[33]	giv[33]	_	_
6-13	632-642	positivity	abstract|abstract[33]	new|giv[33]	_	_
6-14	643-647	rate	abstract[33]	giv[33]	_	_
6-15	648-651	was	_	_	_	_
6-16	652-656	high	_	_	_	_
6-17	657-658	,	_	_	_	_
6-18	659-663	with	_	_	_	_
6-19	664-667	one	quantity[34]	new[34]	_	_
6-20	668-671	out	quantity[34]	new[34]	_	_
6-21	672-674	of	quantity[34]	new[34]	_	_
6-22	675-679	four	quantity[34]|quantity	new[34]|new	_	_
6-23	680-686	having	_	_	_	_
6-24	687-691	been	_	_	_	_
6-25	692-701	diagnosed	_	_	_	_
6-26	702-706	with	_	_	_	_
6-27	707-709	TB	event	giv	coref	7-7
6-28	710-711	.	_	_	_	_

#Text=Fourth , the NNS for one TB patient was relatively high .
7-1	712-718	Fourth	_	_	_	_
7-2	719-720	,	_	_	_	_
7-3	721-724	the	abstract[37]	new[37]	coref	32-11[0_37]
7-4	725-728	NNS	abstract[37]	new[37]	_	_
7-5	729-732	for	abstract[37]	new[37]	_	_
7-6	733-736	one	abstract[37]|person[39]	new[37]|new[39]	_	_
7-7	737-739	TB	abstract[37]|abstract|person[39]	new[37]|giv|new[39]	coref	8-6
7-8	740-747	patient	abstract[37]|person[39]	new[37]|new[39]	_	_
7-9	748-751	was	_	_	_	_
7-10	752-762	relatively	_	_	_	_
7-11	763-767	high	_	_	_	_
7-12	768-769	.	_	_	_	_

#Text=Fifth , the stigma about TB , suspicion about TA , lack of support from political leaders , and low salary for TAs were the major challenges in conducting house-to-house visit for identifying the PTBPs .
8-1	770-775	Fifth	_	_	_	_
8-2	776-777	,	_	_	_	_
8-3	778-781	the	abstract[40]	new[40]	coref	16-29[0_40]
8-4	782-788	stigma	abstract[40]	new[40]	_	_
8-5	789-794	about	abstract[40]	new[40]	_	_
8-6	795-797	TB	abstract[40]|event	new[40]|giv	coref	12-13
8-7	798-799	,	abstract[40]	new[40]	_	_
8-8	800-809	suspicion	abstract[40]|abstract[42]	new[40]|new[42]	_	_
8-9	810-815	about	abstract[40]|abstract[42]	new[40]|new[42]	_	_
8-10	816-818	TA	abstract[40]|abstract[42]|person	new[40]|new[42]|new	_	_
8-11	819-820	,	abstract[40]	new[40]	_	_
8-12	821-825	lack	abstract[40]|abstract[44]	new[40]|new[44]	_	_
8-13	826-828	of	abstract[40]|abstract[44]	new[40]|new[44]	_	_
8-14	829-836	support	abstract[40]|abstract[44]|abstract[45]	new[40]|new[44]|new[45]	coref	27-9[165_45]
8-15	837-841	from	abstract[40]|abstract[44]|abstract[45]	new[40]|new[44]|new[45]	_	_
8-16	842-851	political	abstract[40]|abstract[44]|abstract[45]|person[46]	new[40]|new[44]|new[45]|new[46]	_	_
8-17	852-859	leaders	abstract[40]|abstract[44]|abstract[45]|person[46]	new[40]|new[44]|new[45]|new[46]	_	_
8-18	860-861	,	_	_	_	_
8-19	862-865	and	_	_	_	_
8-20	866-869	low	abstract[47]	new[47]	coref	8-25[49_47]
8-21	870-876	salary	abstract[47]	new[47]	_	_
8-22	877-880	for	abstract[47]	new[47]	_	_
8-23	881-884	TAs	abstract[47]|person	new[47]|new	coref	12-1[78_0]
8-24	885-889	were	_	_	_	_
8-25	890-893	the	abstract[49]	giv[49]	coref	22-1[137_49]
8-26	894-899	major	abstract[49]	giv[49]	_	_
8-27	900-910	challenges	abstract[49]	giv[49]	_	_
8-28	911-913	in	_	_	_	_
8-29	914-924	conducting	_	_	_	_
8-30	925-939	house-to-house	event[50]	new[50]	_	_
8-31	940-945	visit	event[50]	new[50]	_	_
8-32	946-949	for	_	_	_	_
8-33	950-961	identifying	_	_	_	_
8-34	962-965	the	person[51]	giv[51]	coref	9-30[0_51]
8-35	966-971	PTBPs	person[51]	giv[51]	_	_
8-36	972-973	.	_	_	_	_

#Text=Sixth , wage loss , apprehension about the diagnosis , substance abuse , and male dependency of females for seeking care at health facilities were the major challenges for PTBPs to visit the referred health facility .
9-1	974-979	Sixth	_	_	_	_
9-2	980-981	,	_	_	_	_
9-3	982-986	wage	abstract|abstract[53]	new|new[53]	coref|coref	22-4[139_53]|22-4[139_53]
9-4	987-991	loss	abstract[53]	new[53]	_	_
9-5	992-993	,	_	_	_	_
9-6	994-1006	apprehension	abstract[54]	new[54]	coref	9-26[61_54]
9-7	1007-1012	about	abstract[54]	new[54]	_	_
9-8	1013-1016	the	abstract[54]|event[55]	new[54]|giv[55]	coref	18-16[120_55]
9-9	1017-1026	diagnosis	abstract[54]|event[55]	new[54]|giv[55]	_	_
9-10	1027-1028	,	abstract[54]	new[54]	_	_
9-11	1029-1038	substance	abstract[54]|abstract[56]	new[54]|new[56]	coref	25-5[156_56]
9-12	1039-1044	abuse	abstract[54]|abstract[56]	new[54]|new[56]	_	_
9-13	1045-1046	,	abstract[54]	new[54]	_	_
9-14	1047-1050	and	abstract[54]	new[54]	_	_
9-15	1051-1055	male	abstract[54]|abstract[57]	new[54]|new[57]	_	_
9-16	1056-1066	dependency	abstract[54]|abstract[57]	new[54]|new[57]	_	_
9-17	1067-1069	of	abstract[54]|abstract[57]	new[54]|new[57]	_	_
9-18	1070-1077	females	abstract[54]|abstract[57]|person	new[54]|new[57]|new	coref	23-2
9-19	1078-1081	for	_	_	_	_
9-20	1082-1089	seeking	_	_	_	_
9-21	1090-1094	care	abstract[59]	giv[59]	_	_
9-22	1095-1097	at	abstract[59]	giv[59]	_	_
9-23	1098-1104	health	abstract[59]|place[60]	giv[59]|new[60]	coref	18-13[118_60]
9-24	1105-1115	facilities	abstract[59]|place[60]	giv[59]|new[60]	_	_
9-25	1116-1120	were	_	_	_	_
9-26	1121-1124	the	abstract[61]	giv[61]	_	_
9-27	1125-1130	major	abstract[61]	giv[61]	_	_
9-28	1131-1141	challenges	abstract[61]	giv[61]	_	_
9-29	1142-1145	for	abstract[61]	giv[61]	_	_
9-30	1146-1151	PTBPs	abstract[61]|event	giv[61]|giv	coref	15-19[97_0]
9-31	1152-1154	to	_	_	_	_
9-32	1155-1160	visit	_	_	_	_
9-33	1161-1164	the	place[64]	giv[64]	coref	20-20[132_64]
9-34	1165-1173	referred	place[64]	giv[64]	_	_
9-35	1174-1180	health	abstract|place[64]	new|giv[64]	coref	18-13
9-36	1181-1189	facility	place[64]	giv[64]	_	_
9-37	1190-1191	.	_	_	_	_

#Text=We further discuss our study findings in detail .
10-1	1192-1194	We	person	giv	ana	10-4
10-2	1195-1202	further	_	_	_	_
10-3	1203-1210	discuss	_	_	_	_
10-4	1211-1214	our	person|abstract[68]	giv|giv[68]	coref|coref	17-6[112_68]|17-6[112_68]
10-5	1215-1220	study	abstract|abstract[68]	giv|giv[68]	coref	11-3[69_0]
10-6	1221-1229	findings	abstract[68]	giv[68]	_	_
10-7	1230-1232	in	_	_	_	_
10-8	1233-1239	detail	_	_	_	_
10-9	1240-1241	.	_	_	_	_

#Text=First , the study had a low rate of PTBP detection , whereas the previous studies on ACF have consistently shown high rates of PTBP detection .
11-1	1242-1247	First	_	_	_	_
11-2	1248-1249	,	_	_	_	_
11-3	1250-1253	the	abstract[69]	giv[69]	coref	16-4[99_69]
11-4	1254-1259	study	abstract[69]	giv[69]	_	_
11-5	1260-1263	had	_	_	_	_
11-6	1264-1265	a	abstract[70]	giv[70]	_	_
11-7	1266-1269	low	abstract[70]	giv[70]	_	_
11-8	1270-1274	rate	abstract[70]	giv[70]	_	_
11-9	1275-1277	of	abstract[70]	giv[70]	_	_
11-10	1278-1282	PTBP	abstract[70]|abstract|abstract[72]	giv[70]|giv|giv[72]	coref|coref|coref|coref	11-25|11-25[77_72]|11-25|11-25[77_72]
11-11	1283-1292	detection	abstract[70]|abstract[72]	giv[70]|giv[72]	_	_
11-12	1293-1294	,	_	_	_	_
11-13	1295-1302	whereas	_	_	_	_
11-14	1303-1306	the	event[73]	giv[73]	_	_
11-15	1307-1315	previous	event[73]	giv[73]	_	_
11-16	1316-1323	studies	event[73]	giv[73]	_	_
11-17	1324-1326	on	event[73]	giv[73]	_	_
11-18	1327-1330	ACF	event[73]|abstract	giv[73]|giv	coref	13-3
11-19	1331-1335	have	_	_	_	_
11-20	1336-1348	consistently	_	_	_	_
11-21	1349-1354	shown	_	_	_	_
11-22	1355-1359	high	quantity[75]	new[75]	coref	19-9[124_75]
11-23	1360-1365	rates	quantity[75]	new[75]	_	_
11-24	1366-1368	of	quantity[75]	new[75]	_	_
11-25	1369-1373	PTBP	quantity[75]|abstract|abstract[77]	new[75]|giv|giv[77]	coref|coref|coref|coref	14-9[0_77]|14-12|14-9[0_77]|14-12
11-26	1374-1383	detection	quantity[75]|abstract[77]	new[75]|giv[77]	_	_
11-27	1384-1385	.	_	_	_	_

#Text=The TAs failed to individually enquire about symptoms that are suggestive of TB from all those who were enumerated .
12-1	1386-1389	The	person[78]	giv[78]	coref	16-33[0_78]
12-2	1390-1393	TAs	person[78]	giv[78]	_	_
12-3	1394-1400	failed	_	_	_	_
12-4	1401-1403	to	_	_	_	_
12-5	1404-1416	individually	_	_	_	_
12-6	1417-1424	enquire	_	_	_	_
12-7	1425-1430	about	_	_	_	_
12-8	1431-1439	symptoms	abstract	giv	coref	13-11[84_0]
12-9	1440-1444	that	_	_	_	_
12-10	1445-1448	are	_	_	_	_
12-11	1449-1459	suggestive	_	_	_	_
12-12	1460-1462	of	_	_	_	_
12-13	1463-1465	TB	abstract	giv	coref	15-9
12-14	1466-1470	from	_	_	_	_
12-15	1471-1474	all	_	_	_	_
12-16	1475-1480	those	_	_	_	_
12-17	1481-1484	who	_	_	_	_
12-18	1485-1489	were	_	_	_	_
12-19	1490-1500	enumerated	_	_	_	_
12-20	1501-1502	.	_	_	_	_

#Text=As the ACF activity was conducted during the daytime , the symptoms of individuals who were away from home were enquired about by speaking to adult informants .
13-1	1503-1505	As	_	_	_	_
13-2	1506-1509	the	abstract[82]	giv[82]	coref	30-6[181_82]
13-3	1510-1513	ACF	place|abstract[82]	giv|giv[82]	coref	30-6
13-4	1514-1522	activity	abstract[82]	giv[82]	_	_
13-5	1523-1526	was	_	_	_	_
13-6	1527-1536	conducted	_	_	_	_
13-7	1537-1543	during	_	_	_	_
13-8	1544-1547	the	time[83]	new[83]	_	_
13-9	1548-1555	daytime	time[83]	new[83]	_	_
13-10	1556-1557	,	_	_	_	_
13-11	1558-1561	the	abstract[84]	giv[84]	coref	14-17[93_84]
13-12	1562-1570	symptoms	abstract[84]	giv[84]	_	_
13-13	1571-1573	of	abstract[84]	giv[84]	_	_
13-14	1574-1585	individuals	abstract[84]|person	giv[84]|giv	_	_
13-15	1586-1589	who	_	_	_	_
13-16	1590-1594	were	_	_	_	_
13-17	1595-1599	away	_	_	_	_
13-18	1600-1604	from	_	_	_	_
13-19	1605-1609	home	place	new	_	_
13-20	1610-1614	were	_	_	_	_
13-21	1615-1623	enquired	_	_	_	_
13-22	1624-1629	about	_	_	_	_
13-23	1630-1632	by	_	_	_	_
13-24	1633-1641	speaking	_	_	_	_
13-25	1642-1644	to	_	_	_	_
13-26	1645-1650	adult	person[87]	new[87]	coref	15-1[94_87]
13-27	1651-1661	informants	person[87]	new[87]	_	_
13-28	1662-1663	.	_	_	_	_

#Text=Studies in the past have shown that the detection rate of PTBP may be low if the symptoms are not elicited individually .
14-1	1664-1671	Studies	abstract[88]	new[88]	coref	17-1[111_88]
14-2	1672-1674	in	abstract[88]	new[88]	_	_
14-3	1675-1678	the	abstract[88]|abstract[89]	new[88]|new[89]	_	_
14-4	1679-1683	past	abstract[88]|abstract[89]	new[88]|new[89]	_	_
14-5	1684-1688	have	_	_	_	_
14-6	1689-1694	shown	_	_	_	_
14-7	1695-1699	that	_	_	_	_
14-8	1700-1703	the	abstract[91]	new[91]	_	_
14-9	1704-1713	detection	abstract|abstract[91]	giv|new[91]	coref	16-16[103_0]
14-10	1714-1718	rate	abstract[91]	new[91]	_	_
14-11	1719-1721	of	abstract[91]	new[91]	_	_
14-12	1722-1726	PTBP	abstract[91]|event	new[91]|giv	_	_
14-13	1727-1730	may	_	_	_	_
14-14	1731-1733	be	_	_	_	_
14-15	1734-1737	low	_	_	_	_
14-16	1738-1740	if	_	_	_	_
14-17	1741-1744	the	abstract[93]	giv[93]	coref	15-8[96_93]
14-18	1745-1753	symptoms	abstract[93]	giv[93]	_	_
14-19	1754-1757	are	_	_	_	_
14-20	1758-1761	not	_	_	_	_
14-21	1762-1770	elicited	_	_	_	_
14-22	1771-1783	individually	_	_	_	_
14-23	1784-1785	.	_	_	_	_

#Text=The informants might not be aware of the TB symptoms and thus , could have failed to identify the PTBPs among those who were absent during the interview .
15-1	1786-1789	The	person[94]	giv[94]	_	_
15-2	1790-1800	informants	person[94]	giv[94]	_	_
15-3	1801-1806	might	_	_	_	_
15-4	1807-1810	not	_	_	_	_
15-5	1811-1813	be	_	_	_	_
15-6	1814-1819	aware	_	_	_	_
15-7	1820-1822	of	_	_	_	_
15-8	1823-1826	the	abstract[96]	giv[96]	coref	16-25[107_96]
15-9	1827-1829	TB	abstract|abstract[96]	giv|giv[96]	coref	16-25
15-10	1830-1838	symptoms	abstract[96]	giv[96]	_	_
15-11	1839-1842	and	_	_	_	_
15-12	1843-1847	thus	_	_	_	_
15-13	1848-1849	,	_	_	_	_
15-14	1850-1855	could	_	_	_	_
15-15	1856-1860	have	_	_	_	_
15-16	1861-1867	failed	_	_	_	_
15-17	1868-1870	to	_	_	_	_
15-18	1871-1879	identify	_	_	_	_
15-19	1880-1883	the	event[97]	giv[97]	coref	18-10[0_97]
15-20	1884-1889	PTBPs	event[97]	giv[97]	_	_
15-21	1890-1895	among	_	_	_	_
15-22	1896-1901	those	_	_	_	_
15-23	1902-1905	who	_	_	_	_
15-24	1906-1910	were	_	_	_	_
15-25	1911-1917	absent	_	_	_	_
15-26	1918-1924	during	_	_	_	_
15-27	1925-1928	the	event[98]	new[98]	_	_
15-28	1929-1938	interview	event[98]	new[98]	_	_
15-29	1939-1940	.	_	_	_	_

#Text=As explored in the qualitative study , the other potential reasons for low rate of PTBP detection are hesitancy to disclose the details of TB symptoms due to stigma and distrust about TAs .
16-1	1941-1943	As	_	_	_	_
16-2	1944-1952	explored	_	_	_	_
16-3	1953-1955	in	_	_	_	_
16-4	1956-1959	the	abstract[99]	giv[99]	_	_
16-5	1960-1971	qualitative	abstract[99]	giv[99]	_	_
16-6	1972-1977	study	abstract[99]	giv[99]	_	_
16-7	1978-1979	,	_	_	_	_
16-8	1980-1983	the	abstract[100]	new[100]	coref	16-19[0_100]
16-9	1984-1989	other	abstract[100]	new[100]	_	_
16-10	1990-1999	potential	abstract[100]	new[100]	_	_
16-11	2000-2007	reasons	abstract[100]	new[100]	_	_
16-12	2008-2011	for	abstract[100]	new[100]	_	_
16-13	2012-2015	low	abstract[100]|abstract[101]	new[100]|new[101]	_	_
16-14	2016-2020	rate	abstract[100]|abstract[101]	new[100]|new[101]	_	_
16-15	2021-2023	of	abstract[100]|abstract[101]	new[100]|new[101]	_	_
16-16	2024-2028	PTBP	abstract[100]|abstract[101]|person|event[103]	new[100]|new[101]|giv|giv[103]	_	_
16-17	2029-2038	detection	abstract[100]|abstract[101]|event[103]	new[100]|new[101]|giv[103]	_	_
16-18	2039-2042	are	_	_	_	_
16-19	2043-2052	hesitancy	abstract	giv	coref	21-8[135_0]
16-20	2053-2055	to	_	_	_	_
16-21	2056-2064	disclose	_	_	_	_
16-22	2065-2068	the	abstract[105]	new[105]	_	_
16-23	2069-2076	details	abstract[105]	new[105]	_	_
16-24	2077-2079	of	abstract[105]	new[105]	_	_
16-25	2080-2082	TB	abstract[105]|abstract|abstract[107]	new[105]|giv|giv[107]	coref|coref|coref|coref	18-16|30-19[0_107]|18-16|30-19[0_107]
16-26	2083-2091	symptoms	abstract[105]|abstract[107]	new[105]|giv[107]	_	_
16-27	2092-2095	due	_	_	_	_
16-28	2096-2098	to	_	_	_	_
16-29	2099-2105	stigma	abstract	giv	_	_
16-30	2106-2109	and	_	_	_	_
16-31	2110-2118	distrust	abstract[109]	new[109]	_	_
16-32	2119-2124	about	abstract[109]	new[109]	_	_
16-33	2125-2128	TAs	abstract[109]|abstract	new[109]|giv	coref	20-12
16-34	2129-2130	.	_	_	_	_

#Text=Some other studies also revealed similar findings .
17-1	2131-2135	Some	event[111]	giv[111]	coref	19-1[121_111]
17-2	2136-2141	other	event[111]	giv[111]	_	_
17-3	2142-2149	studies	event[111]	giv[111]	_	_
17-4	2150-2154	also	_	_	_	_
17-5	2155-2163	revealed	_	_	_	_
17-6	2164-2171	similar	abstract[112]	giv[112]	coref	19-6[122_112]
17-7	2172-2180	findings	abstract[112]	giv[112]	_	_
17-8	2181-2182	.	_	_	_	_

#Text=The second finding is the high attrition rate among PTBPs referred to health facilities for TB diagnosis .
18-1	2183-2186	The	abstract[113]	new[113]	coref	18-5[115_113]
18-2	2187-2193	second	abstract[113]	new[113]	_	_
18-3	2194-2201	finding	abstract[113]	new[113]	_	_
18-4	2202-2204	is	_	_	_	_
18-5	2205-2208	the	abstract[115]	giv[115]	coref	20-1[127_115]
18-6	2209-2213	high	abstract[115]	giv[115]	_	_
18-7	2214-2223	attrition	event|abstract[115]	giv|giv[115]	coref	19-9
18-8	2224-2228	rate	abstract[115]	giv[115]	_	_
18-9	2229-2234	among	abstract[115]	giv[115]	_	_
18-10	2235-2240	PTBPs	abstract[115]|person	giv[115]|giv	coref	20-17
18-11	2241-2249	referred	_	_	_	_
18-12	2250-2252	to	_	_	_	_
18-13	2253-2259	health	abstract|place[118]	giv|giv[118]	coref|coref|coref|coref	22-12|22-12[142_118]|22-12|22-12[142_118]
18-14	2260-2270	facilities	place[118]	giv[118]	_	_
18-15	2271-2274	for	place[118]	giv[118]	_	_
18-16	2275-2277	TB	place[118]|abstract|event[120]	giv[118]|giv|giv[120]	coref|coref|coref|coref	28-6|28-6[171_120]|28-6|28-6[171_120]
18-17	2278-2287	diagnosis	place[118]|event[120]	giv[118]|giv[120]	_	_
18-18	2288-2289	.	_	_	_	_

#Text=Previous studies have also reported similar findings with attrition rates ranging from 39 % to 80 % .
19-1	2290-2298	Previous	event[121]	giv[121]	coref	33-1[197_121]
19-2	2299-2306	studies	event[121]	giv[121]	_	_
19-3	2307-2311	have	_	_	_	_
19-4	2312-2316	also	_	_	_	_
19-5	2317-2325	reported	_	_	_	_
19-6	2326-2333	similar	abstract[122]	giv[122]	_	_
19-7	2334-2342	findings	abstract[122]	giv[122]	_	_
19-8	2343-2347	with	abstract[122]	giv[122]	_	_
19-9	2348-2357	attrition	abstract[122]|event|quantity[124]	giv[122]|giv|giv[124]	coref|coref	21-11[136_0]|21-11[136_0]
19-10	2358-2363	rates	abstract[122]|quantity[124]	giv[122]|giv[124]	_	_
19-11	2364-2371	ranging	_	_	_	_
19-12	2372-2376	from	_	_	_	_
19-13	2377-2379	39	quantity[125]	new[125]	_	_
19-14	2380-2381	%	quantity[125]	new[125]	_	_
19-15	2382-2384	to	_	_	_	_
19-16	2385-2387	80	quantity[126]	new[126]	_	_
19-17	2388-2389	%	quantity[126]	new[126]	_	_
19-18	2390-2391	.	_	_	_	_

#Text=The rate was high in spite of repeated house visits by TAs to counsel and encourage PTBPs to visit the health facility .
20-1	2392-2395	The	abstract[127]	giv[127]	coref	23-4[148_127]
20-2	2396-2400	rate	abstract[127]	giv[127]	_	_
20-3	2401-2404	was	_	_	_	_
20-4	2405-2409	high	_	_	_	_
20-5	2410-2412	in	_	_	_	_
20-6	2413-2418	spite	_	_	_	_
20-7	2419-2421	of	_	_	_	_
20-8	2422-2430	repeated	abstract[129]	giv[129]	coref	22-10[0_129]
20-9	2431-2436	house	place|abstract[129]	new|giv[129]	_	_
20-10	2437-2443	visits	abstract[129]	giv[129]	_	_
20-11	2444-2446	by	abstract[129]	giv[129]	_	_
20-12	2447-2450	TAs	abstract[129]|person	giv[129]|giv	coref	31-3[186_0]
20-13	2451-2453	to	_	_	_	_
20-14	2454-2461	counsel	_	_	_	_
20-15	2462-2465	and	_	_	_	_
20-16	2466-2475	encourage	_	_	_	_
20-17	2476-2481	PTBPs	person	giv	coref	25-1[154_0]
20-18	2482-2484	to	_	_	_	_
20-19	2485-2490	visit	_	_	_	_
20-20	2491-2494	the	place[132]	giv[132]	coref	23-19[151_132]
20-21	2495-2501	health	place[132]	giv[132]	_	_
20-22	2502-2510	facility	place[132]	giv[132]	_	_
20-23	2511-2512	.	_	_	_	_

#Text=The qualitative interviews provided good insight about potential reasons for such high attrition .
21-1	2513-2516	The	abstract[133]	new[133]	_	_
21-2	2517-2528	qualitative	abstract[133]	new[133]	_	_
21-3	2529-2539	interviews	abstract[133]	new[133]	_	_
21-4	2540-2548	provided	_	_	_	_
21-5	2549-2553	good	abstract[134]	new[134]	_	_
21-6	2554-2561	insight	abstract[134]	new[134]	_	_
21-7	2562-2567	about	abstract[134]	new[134]	_	_
21-8	2568-2577	potential	abstract[134]|abstract[135]	new[134]|giv[135]	coref	22-21[145_135]
21-9	2578-2585	reasons	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
21-10	2586-2589	for	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
21-11	2590-2594	such	abstract[134]|abstract[135]|event[136]	new[134]|giv[135]|giv[136]	coref	23-5[0_136]
21-12	2595-2599	high	abstract[134]|abstract[135]|event[136]	new[134]|giv[135]|giv[136]	_	_
21-13	2600-2609	attrition	abstract[134]|abstract[135]|event[136]	new[134]|giv[135]|giv[136]	_	_
21-14	2610-2611	.	_	_	_	_

#Text=The wage or work loss due to travel and visits to health facilities during the day time was one of the major reasons .
22-1	2612-2615	The	abstract[137]	giv[137]	_	_
22-2	2616-2620	wage	abstract[137]	giv[137]	_	_
22-3	2621-2623	or	abstract[137]	giv[137]	_	_
22-4	2624-2628	work	abstract[137]|abstract|abstract[139]	giv[137]|new|giv[139]	_	_
22-5	2629-2633	loss	abstract[137]|abstract[139]	giv[137]|giv[139]	_	_
22-6	2634-2637	due	_	_	_	_
22-7	2638-2640	to	_	_	_	_
22-8	2641-2647	travel	_	_	_	_
22-9	2648-2651	and	_	_	_	_
22-10	2652-2658	visits	abstract	giv	coref	36-1[218_0]
22-11	2659-2661	to	_	_	_	_
22-12	2662-2668	health	abstract|place[142]	giv|giv[142]	coref|coref	26-13|26-13
22-13	2669-2679	facilities	place[142]	giv[142]	_	_
22-14	2680-2686	during	place[142]	giv[142]	_	_
22-15	2687-2690	the	place[142]|time[143]	giv[142]|new[143]	coref	41-27[255_143]
22-16	2691-2694	day	place[142]|time[143]	giv[142]|new[143]	_	_
22-17	2695-2699	time	place[142]|time[143]	giv[142]|new[143]	_	_
22-18	2700-2703	was	_	_	_	_
22-19	2704-2707	one	abstract[144]	new[144]	_	_
22-20	2708-2710	of	abstract[144]	new[144]	_	_
22-21	2711-2714	the	abstract[144]|abstract[145]	new[144]|giv[145]	coref	27-3[163_145]
22-22	2715-2720	major	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
22-23	2721-2728	reasons	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
22-24	2729-2730	.	_	_	_	_

#Text=Among females , the attrition rate was high as they were dependent on male family members to visit the health facility .
23-1	2731-2736	Among	_	_	_	_
23-2	2737-2744	females	person	giv	ana	23-10
23-3	2745-2746	,	_	_	_	_
23-4	2747-2750	the	abstract[148]	giv[148]	coref	28-3[169_148]
23-5	2751-2760	attrition	event|abstract[148]	giv|giv[148]	coref	25-11[157_0]
23-6	2761-2765	rate	abstract[148]	giv[148]	_	_
23-7	2766-2769	was	_	_	_	_
23-8	2770-2774	high	_	_	_	_
23-9	2775-2777	as	_	_	_	_
23-10	2778-2782	they	person	giv	_	_
23-11	2783-2787	were	_	_	_	_
23-12	2788-2797	dependent	_	_	_	_
23-13	2798-2800	on	_	_	_	_
23-14	2801-2805	male	person[150]	new[150]	coref	41-20[252_150]
23-15	2806-2812	family	person[150]	new[150]	_	_
23-16	2813-2820	members	person[150]	new[150]	_	_
23-17	2821-2823	to	_	_	_	_
23-18	2824-2829	visit	_	_	_	_
23-19	2830-2833	the	place[151]	giv[151]	coref	28-12[173_151]
23-20	2834-2840	health	place[151]	giv[151]	_	_
23-21	2841-2849	facility	place[151]	giv[151]	_	_
23-22	2850-2851	.	_	_	_	_

#Text=Difficulties in counselling
24-1	2852-2864	Difficulties	abstract[152]	new[152]	_	_
24-2	2865-2867	in	abstract[152]	new[152]	_	_
24-3	2868-2879	counselling	abstract[152]|event	new[152]|new	_	_

#Text=PTBPs with alcohol and other substance abuse also contributed to the attrition .
25-1	2880-2885	PTBPs	event[154]	giv[154]	coref	27-14[0_154]
25-2	2886-2890	with	event[154]	giv[154]	_	_
25-3	2891-2898	alcohol	event[154]|substance	giv[154]|new	_	_
25-4	2899-2902	and	event[154]	giv[154]	_	_
25-5	2903-2908	other	event[154]|abstract[156]	giv[154]|giv[156]	_	_
25-6	2909-2918	substance	event[154]|abstract[156]	giv[154]|giv[156]	_	_
25-7	2919-2924	abuse	event[154]|abstract[156]	giv[154]|giv[156]	_	_
25-8	2925-2929	also	_	_	_	_
25-9	2930-2941	contributed	_	_	_	_
25-10	2942-2944	to	_	_	_	_
25-11	2945-2948	the	event[157]	giv[157]	coref	34-14[0_157]
25-12	2949-2958	attrition	event[157]	giv[157]	_	_
25-13	2959-2960	.	_	_	_	_

#Text=The other important issue was general distrust and unhappiness about the public health system among the public .
26-1	2961-2964	The	abstract[158]	new[158]	coref	26-6[159_158]
26-2	2965-2970	other	abstract[158]	new[158]	_	_
26-3	2971-2980	important	abstract[158]	new[158]	_	_
26-4	2981-2986	issue	abstract[158]	new[158]	_	_
26-5	2987-2990	was	_	_	_	_
26-6	2991-2998	general	abstract[159]	giv[159]	_	_
26-7	2999-3007	distrust	abstract[159]	giv[159]	_	_
26-8	3008-3011	and	_	_	_	_
26-9	3012-3023	unhappiness	_	_	_	_
26-10	3024-3029	about	_	_	_	_
26-11	3030-3033	the	abstract[161]	new[161]	_	_
26-12	3034-3040	public	abstract[161]	new[161]	_	_
26-13	3041-3047	health	abstract|abstract[161]	giv|new[161]	_	_
26-14	3048-3054	system	abstract[161]	new[161]	_	_
26-15	3055-3060	among	abstract[161]	new[161]	_	_
26-16	3061-3064	the	abstract[161]|person[162]	new[161]|new[162]	_	_
26-17	3065-3071	public	abstract[161]|person[162]	new[161]|new[162]	_	_
26-18	3072-3073	.	_	_	_	_

#Text=Thus , these reasons warrant the provision of financial support and assistance to PTBPs to undergo diagnostic tests .
27-1	3074-3078	Thus	_	_	_	_
27-2	3079-3080	,	_	_	_	_
27-3	3081-3086	these	abstract[163]	giv[163]	_	_
27-4	3087-3094	reasons	abstract[163]	giv[163]	_	_
27-5	3095-3102	warrant	_	_	_	_
27-6	3103-3106	the	abstract[164]	new[164]	_	_
27-7	3107-3116	provision	abstract[164]	new[164]	_	_
27-8	3117-3119	of	abstract[164]	new[164]	_	_
27-9	3120-3129	financial	abstract[164]|abstract[165]	new[164]|giv[165]	_	_
27-10	3130-3137	support	abstract[164]|abstract[165]	new[164]|giv[165]	_	_
27-11	3138-3141	and	abstract[164]	new[164]	_	_
27-12	3142-3152	assistance	abstract[164]|abstract[166]	new[164]|new[166]	_	_
27-13	3153-3155	to	abstract[164]|abstract[166]	new[164]|new[166]	_	_
27-14	3156-3161	PTBPs	abstract[164]|abstract[166]|person	new[164]|new[166]|giv	coref	28-9[172_0]
27-15	3162-3164	to	_	_	_	_
27-16	3165-3172	undergo	_	_	_	_
27-17	3173-3183	diagnostic	abstract[168]	new[168]	_	_
27-18	3184-3189	tests	abstract[168]	new[168]	_	_
27-19	3190-3191	.	_	_	_	_

#Text=Third , the rate of TB diagnosis among those PTBPs visiting a health facility was high .
28-1	3192-3197	Third	_	_	_	_
28-2	3198-3199	,	_	_	_	_
28-3	3200-3203	the	abstract[169]	giv[169]	_	_
28-4	3204-3208	rate	abstract[169]	giv[169]	_	_
28-5	3209-3211	of	abstract[169]	giv[169]	_	_
28-6	3212-3214	TB	abstract[169]|event|event[171]	giv[169]|giv|giv[171]	coref|coref	32-13|32-13
28-7	3215-3224	diagnosis	abstract[169]|event[171]	giv[169]|giv[171]	_	_
28-8	3225-3230	among	abstract[169]|event[171]	giv[169]|giv[171]	_	_
28-9	3231-3236	those	abstract[169]|event[171]|person[172]	giv[169]|giv[171]|giv[172]	ana	29-9[176_172]
28-10	3237-3242	PTBPs	abstract[169]|event[171]|person[172]	giv[169]|giv[171]|giv[172]	_	_
28-11	3243-3251	visiting	_	_	_	_
28-12	3252-3253	a	place[173]	giv[173]	ana	29-1[0_173]
28-13	3254-3260	health	place[173]	giv[173]	_	_
28-14	3261-3269	facility	place[173]	giv[173]	_	_
28-15	3270-3273	was	_	_	_	_
28-16	3274-3278	high	_	_	_	_
28-17	3279-3280	.	_	_	_	_

#Text=This could be due to the fact that only those with perceived need reached the health facility .
29-1	3281-3285	This	place	giv	coref	29-15[178_0]
29-2	3286-3291	could	_	_	_	_
29-3	3292-3294	be	_	_	_	_
29-4	3295-3298	due	_	_	_	_
29-5	3299-3301	to	_	_	_	_
29-6	3302-3305	the	abstract[175]	new[175]	_	_
29-7	3306-3310	fact	abstract[175]	new[175]	_	_
29-8	3311-3315	that	abstract[175]	new[175]	_	_
29-9	3316-3320	only	abstract[175]|person[176]	new[175]|giv[176]	coref	30-2[0_176]
29-10	3321-3326	those	abstract[175]|person[176]	new[175]|giv[176]	_	_
29-11	3327-3331	with	abstract[175]|person[176]	new[175]|giv[176]	_	_
29-12	3332-3341	perceived	abstract[175]|person[176]|abstract[177]	new[175]|giv[176]|new[177]	_	_
29-13	3342-3346	need	abstract[175]|person[176]|abstract[177]	new[175]|giv[176]|new[177]	_	_
29-14	3347-3354	reached	abstract[175]	new[175]	_	_
29-15	3355-3358	the	abstract[175]|place[178]	new[175]|giv[178]	_	_
29-16	3359-3365	health	abstract[175]|place[178]	new[175]|giv[178]	_	_
29-17	3366-3374	facility	abstract[175]|place[178]	new[175]|giv[178]	_	_
29-18	3375-3376	.	_	_	_	_

#Text=Though PTBPs were identified by ACF activity , the decision to visit largely depended on the severity of symptoms and thus mimicked the passive case finding .
30-1	3377-3383	Though	_	_	_	_
30-2	3384-3389	PTBPs	event	giv	coref	31-15[190_0]
30-3	3390-3394	were	_	_	_	_
30-4	3395-3405	identified	_	_	_	_
30-5	3406-3408	by	_	_	_	_
30-6	3409-3412	ACF	place|abstract[181]	giv|giv[181]	coref|coref|coref|coref	32-7|35-7[211_181]|32-7|35-7[211_181]
30-7	3413-3421	activity	abstract[181]	giv[181]	_	_
30-8	3422-3423	,	_	_	_	_
30-9	3424-3427	the	abstract[182]	new[182]	_	_
30-10	3428-3436	decision	abstract[182]	new[182]	_	_
30-11	3437-3439	to	_	_	_	_
30-12	3440-3445	visit	_	_	_	_
30-13	3446-3453	largely	_	_	_	_
30-14	3454-3462	depended	_	_	_	_
30-15	3463-3465	on	_	_	_	_
30-16	3466-3469	the	abstract[183]	new[183]	_	_
30-17	3470-3478	severity	abstract[183]	new[183]	_	_
30-18	3479-3481	of	abstract[183]	new[183]	_	_
30-19	3482-3490	symptoms	abstract[183]|abstract	new[183]|giv	coref	31-17[191_0]
30-20	3491-3494	and	_	_	_	_
30-21	3495-3499	thus	_	_	_	_
30-22	3500-3508	mimicked	_	_	_	_
30-23	3509-3512	the	abstract[185]	new[185]	coref	37-6[0_185]
30-24	3513-3520	passive	abstract[185]	new[185]	_	_
30-25	3521-3525	case	abstract[185]	new[185]	_	_
30-26	3526-3533	finding	_	_	_	_
30-27	3534-3535	.	_	_	_	_

#Text=Also , the TAs might have given more preference to referral and linkage of PTBPs with severe and multiple symptoms rather than those with mild symptoms .
31-1	3536-3540	Also	_	_	_	_
31-2	3541-3542	,	_	_	_	_
31-3	3543-3546	the	abstract[186]	giv[186]	_	_
31-4	3547-3550	TAs	abstract[186]	giv[186]	_	_
31-5	3551-3556	might	_	_	_	_
31-6	3557-3561	have	_	_	_	_
31-7	3562-3567	given	_	_	_	_
31-8	3568-3572	more	abstract[187]	new[187]	_	_
31-9	3573-3583	preference	abstract[187]	new[187]	_	_
31-10	3584-3586	to	abstract[187]	new[187]	_	_
31-11	3587-3595	referral	abstract[187]|abstract	new[187]|new	_	_
31-12	3596-3599	and	abstract[187]	new[187]	_	_
31-13	3600-3607	linkage	abstract[187]|abstract[189]	new[187]|new[189]	_	_
31-14	3608-3610	of	abstract[187]|abstract[189]	new[187]|new[189]	_	_
31-15	3611-3616	PTBPs	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	coref	34-17[0_190]
31-16	3617-3621	with	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	_	_
31-17	3622-3628	severe	abstract[187]|abstract[189]|event[190]|abstract[191]	new[187]|new[189]|giv[190]|giv[191]	coref	31-25[192_191]
31-18	3629-3632	and	abstract[187]|abstract[189]|event[190]|abstract[191]	new[187]|new[189]|giv[190]|giv[191]	_	_
31-19	3633-3641	multiple	abstract[187]|abstract[189]|event[190]|abstract[191]	new[187]|new[189]|giv[190]|giv[191]	_	_
31-20	3642-3650	symptoms	abstract[187]|abstract[189]|event[190]|abstract[191]	new[187]|new[189]|giv[190]|giv[191]	_	_
31-21	3651-3657	rather	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	_	_
31-22	3658-3662	than	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	_	_
31-23	3663-3668	those	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	_	_
31-24	3669-3673	with	abstract[187]|abstract[189]|event[190]	new[187]|new[189]|giv[190]	_	_
31-25	3674-3678	mild	abstract[187]|abstract[189]|event[190]|abstract[192]	new[187]|new[189]|giv[190]|giv[192]	coref	35-18[215_192]
31-26	3679-3687	symptoms	abstract[187]|abstract[189]|event[190]|abstract[192]	new[187]|new[189]|giv[190]|giv[192]	_	_
31-27	3688-3689	.	_	_	_	_

#Text=Fourth , the overall yield of ACF was low and NNS for TB was high .
32-1	3690-3696	Fourth	_	_	_	_
32-2	3697-3698	,	_	_	_	_
32-3	3699-3702	the	abstract[193]	new[193]	_	_
32-4	3703-3710	overall	abstract[193]	new[193]	_	_
32-5	3711-3716	yield	abstract[193]	new[193]	_	_
32-6	3717-3719	of	abstract[193]	new[193]	_	_
32-7	3720-3723	ACF	abstract[193]|object	new[193]|giv	coref	40-21
32-8	3724-3727	was	_	_	_	_
32-9	3728-3731	low	_	_	_	_
32-10	3732-3735	and	_	_	_	_
32-11	3736-3739	NNS	abstract	giv	coref	33-5[198_0]
32-12	3740-3743	for	_	_	_	_
32-13	3744-3746	TB	quantity	giv	coref	33-13
32-14	3747-3750	was	_	_	_	_
32-15	3751-3755	high	_	_	_	_
32-16	3756-3757	.	_	_	_	_

#Text=Previous studies have reported lower NNS on mass screening in high burden TB settings .
33-1	3758-3766	Previous	event[197]	giv[197]	coref	43-10[269_197]
33-2	3767-3774	studies	event[197]	giv[197]	_	_
33-3	3775-3779	have	_	_	_	_
33-4	3780-3788	reported	_	_	_	_
33-5	3789-3794	lower	abstract[198]	giv[198]	coref	34-5[205_198]
33-6	3795-3798	NNS	abstract[198]	giv[198]	_	_
33-7	3799-3801	on	abstract[198]	giv[198]	_	_
33-8	3802-3806	mass	abstract[198]|quantity|abstract[200]	giv[198]|new|new[200]	_	_
33-9	3807-3816	screening	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
33-10	3817-3819	in	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
33-11	3820-3824	high	abstract[198]|abstract[200]|abstract[201]|abstract[203]	giv[198]|new[200]|new[201]|new[203]	coref|coref	39-7[234_203]|39-7[234_203]
33-12	3825-3831	burden	abstract[198]|abstract[200]|abstract[201]|abstract[203]	giv[198]|new[200]|new[201]|new[203]	_	_
33-13	3832-3834	TB	abstract[198]|abstract[200]|abstract|abstract[203]	giv[198]|new[200]|giv|new[203]	coref	35-18
33-14	3835-3843	settings	abstract[198]|abstract[200]|abstract[203]	giv[198]|new[200]|new[203]	_	_
33-15	3844-3845	.	_	_	_	_

#Text=A potential reason for high NNS might be the low detection and high attrition rate of PTBPs .
34-1	3846-3847	A	abstract[204]	new[204]	coref	34-9[206_204]
34-2	3848-3857	potential	abstract[204]	new[204]	_	_
34-3	3858-3864	reason	abstract[204]	new[204]	_	_
34-4	3865-3868	for	abstract[204]	new[204]	_	_
34-5	3869-3873	high	abstract[204]|abstract[205]	new[204]|giv[205]	coref	35-2[210_205]
34-6	3874-3877	NNS	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
34-7	3878-3883	might	_	_	_	_
34-8	3884-3886	be	_	_	_	_
34-9	3887-3890	the	abstract[206]	giv[206]	coref	37-4[226_206]
34-10	3891-3894	low	abstract[206]	giv[206]	_	_
34-11	3895-3904	detection	abstract[206]	giv[206]	_	_
34-12	3905-3908	and	abstract[206]	giv[206]	_	_
34-13	3909-3913	high	abstract[206]|quantity[208]	giv[206]|new[208]	_	_
34-14	3914-3923	attrition	abstract[206]|event|quantity[208]	giv[206]|giv|new[208]	_	_
34-15	3924-3928	rate	abstract[206]|quantity[208]	giv[206]|new[208]	_	_
34-16	3929-3931	of	abstract[206]|quantity[208]	giv[206]|new[208]	_	_
34-17	3932-3937	PTBPs	abstract[206]|quantity[208]|abstract	giv[206]|new[208]|giv	_	_
34-18	3938-3939	.	_	_	_	_

#Text=Although the NNS is high , the activity is still worthwhile as it indirectly sensitizes households on TB symptoms and thus creates awareness in the community .
35-1	3940-3948	Although	_	_	_	_
35-2	3949-3952	the	abstract[210]	giv[210]	_	_
35-3	3953-3956	NNS	abstract[210]	giv[210]	_	_
35-4	3957-3959	is	_	_	_	_
35-5	3960-3964	high	_	_	_	_
35-6	3965-3966	,	_	_	_	_
35-7	3967-3970	the	abstract[211]	giv[211]	ana	35-13[0_211]
35-8	3971-3979	activity	abstract[211]	giv[211]	_	_
35-9	3980-3982	is	_	_	_	_
35-10	3983-3988	still	_	_	_	_
35-11	3989-3999	worthwhile	_	_	_	_
35-12	4000-4002	as	_	_	_	_
35-13	4003-4005	it	abstract	giv	_	_
35-14	4006-4016	indirectly	_	_	_	_
35-15	4017-4027	sensitizes	_	_	_	_
35-16	4028-4038	households	place	new	_	_
35-17	4039-4041	on	_	_	_	_
35-18	4042-4044	TB	abstract|abstract[215]	giv|giv[215]	coref|coref	37-14|37-14
35-19	4045-4053	symptoms	abstract[215]	giv[215]	_	_
35-20	4054-4057	and	_	_	_	_
35-21	4058-4062	thus	_	_	_	_
35-22	4063-4070	creates	_	_	_	_
35-23	4071-4080	awareness	abstract	new	_	_
35-24	4081-4083	in	_	_	_	_
35-25	4084-4087	the	abstract[217]	new[217]	coref	36-4[219_217]
35-26	4088-4097	community	abstract[217]	new[217]	_	_
35-27	4098-4099	.	_	_	_	_

#Text=Regular visits to the same community ( six days a week ) is gradually leading to good rapport building with the community .
36-1	4100-4107	Regular	abstract[218]	giv[218]	_	_
36-2	4108-4114	visits	abstract[218]	giv[218]	_	_
36-3	4115-4117	to	abstract[218]	giv[218]	_	_
36-4	4118-4121	the	abstract[218]|abstract[219]	giv[218]|giv[219]	coref	36-21[223_219]
36-5	4122-4126	same	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
36-6	4127-4136	community	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
36-7	4137-4138	(	_	_	_	_
36-8	4139-4142	six	time[220]	new[220]	appos	36-10[221_220]
36-9	4143-4147	days	time[220]	new[220]	_	_
36-10	4148-4149	a	time[221]	giv[221]	_	_
36-11	4150-4154	week	time[221]	giv[221]	_	_
36-12	4155-4156	)	_	_	_	_
36-13	4157-4159	is	_	_	_	_
36-14	4160-4169	gradually	_	_	_	_
36-15	4170-4177	leading	_	_	_	_
36-16	4178-4180	to	_	_	_	_
36-17	4181-4185	good	abstract[222]	new[222]	_	_
36-18	4186-4193	rapport	abstract[222]	new[222]	_	_
36-19	4194-4202	building	_	_	_	_
36-20	4203-4207	with	_	_	_	_
36-21	4208-4211	the	abstract[223]	giv[223]	ana	37-1[0_223]
36-22	4212-4221	community	abstract[223]	giv[223]	_	_
36-23	4222-4223	.	_	_	_	_

#Text=This might improve the overall case detection in the community and contribute to TB control efforts .
37-1	4224-4228	This	abstract	giv	coref	37-9[227_0]
37-2	4229-4234	might	_	_	_	_
37-3	4235-4242	improve	_	_	_	_
37-4	4243-4246	the	abstract[226]	giv[226]	_	_
37-5	4247-4254	overall	abstract[226]	giv[226]	_	_
37-6	4255-4259	case	abstract|abstract[226]	giv|giv[226]	_	_
37-7	4260-4269	detection	abstract[226]	giv[226]	_	_
37-8	4270-4272	in	abstract[226]	giv[226]	_	_
37-9	4273-4276	the	abstract[226]|abstract[227]	giv[226]|giv[227]	_	_
37-10	4277-4286	community	abstract[226]|abstract[227]	giv[226]|giv[227]	_	_
37-11	4287-4290	and	_	_	_	_
37-12	4291-4301	contribute	_	_	_	_
37-13	4302-4304	to	_	_	_	_
37-14	4305-4307	TB	abstract|abstract[230]	giv|new[230]	_	_
37-15	4308-4315	control	abstract|abstract[230]	new|new[230]	_	_
37-16	4316-4323	efforts	abstract[230]	new[230]	_	_
37-17	4324-4325	.	_	_	_	_

#Text=The study has several strengths .
38-1	4326-4329	The	abstract[231]	new[231]	ana	39-3[0_231]
38-2	4330-4335	study	abstract[231]	new[231]	_	_
38-3	4336-4339	has	_	_	_	_
38-4	4340-4347	several	abstract[232]	new[232]	_	_
38-5	4348-4357	strengths	abstract[232]	new[232]	_	_
38-6	4358-4359	.	_	_	_	_

#Text=First , it was conducted under programmatic settings and reflects the field realities .
39-1	4360-4365	First	_	_	_	_
39-2	4366-4367	,	_	_	_	_
39-3	4368-4370	it	abstract	giv	coref	41-3[246_0]
39-4	4371-4374	was	_	_	_	_
39-5	4375-4384	conducted	_	_	_	_
39-6	4385-4390	under	_	_	_	_
39-7	4391-4403	programmatic	abstract[234]	giv[234]	_	_
39-8	4404-4412	settings	abstract[234]	giv[234]	_	_
39-9	4413-4416	and	_	_	_	_
39-10	4417-4425	reflects	_	_	_	_
39-11	4426-4429	the	abstract[236]	new[236]	_	_
39-12	4430-4435	field	abstract|abstract[236]	new|new[236]	_	_
39-13	4436-4445	realities	abstract[236]	new[236]	_	_
39-14	4446-4447	.	_	_	_	_

#Text=Second , we used a mixed methods design , which provided considerable insights into challenges involved in the implementation of ACF and enabled us to interpret the quantitative results .
40-1	4448-4454	Second	_	_	_	_
40-2	4455-4456	,	_	_	_	_
40-3	4457-4459	we	person	acc	ana	40-24
40-4	4460-4464	used	_	_	_	_
40-5	4465-4466	a	abstract[239]	new[239]	_	_
40-6	4467-4472	mixed	abstract[239]	new[239]	_	_
40-7	4473-4480	methods	abstract|abstract[239]	new|new[239]	_	_
40-8	4481-4487	design	abstract[239]	new[239]	_	_
40-9	4488-4489	,	_	_	_	_
40-10	4490-4495	which	_	_	_	_
40-11	4496-4504	provided	_	_	_	_
40-12	4505-4517	considerable	abstract[240]	new[240]	_	_
40-13	4518-4526	insights	abstract[240]	new[240]	_	_
40-14	4527-4531	into	abstract[240]	new[240]	_	_
40-15	4532-4542	challenges	abstract[240]|abstract	new[240]|new	_	_
40-16	4543-4551	involved	_	_	_	_
40-17	4552-4554	in	_	_	_	_
40-18	4555-4558	the	abstract[242]	new[242]	_	_
40-19	4559-4573	implementation	abstract[242]	new[242]	_	_
40-20	4574-4576	of	abstract[242]	new[242]	_	_
40-21	4577-4580	ACF	abstract[242]|abstract	new[242]|giv	coref	41-35
40-22	4581-4584	and	_	_	_	_
40-23	4585-4592	enabled	_	_	_	_
40-24	4593-4595	us	person	giv	ana	41-18
40-25	4596-4598	to	_	_	_	_
40-26	4599-4608	interpret	_	_	_	_
40-27	4609-4612	the	abstract[245]	new[245]	_	_
40-28	4613-4625	quantitative	abstract[245]	new[245]	_	_
40-29	4626-4633	results	abstract[245]	new[245]	_	_
40-30	4634-4635	.	_	_	_	_

#Text=Third , the study has a relatively large sample size and there was no selection bias as we included all the individuals who were enumerated during the study reference period in 60 wards where ACF is implemented .
41-1	4636-4641	Third	_	_	_	_
41-2	4642-4643	,	_	_	_	_
41-3	4644-4647	the	abstract[246]	giv[246]	coref	41-28[0_246]
41-4	4648-4653	study	abstract[246]	giv[246]	_	_
41-5	4654-4657	has	_	_	_	_
41-6	4658-4659	a	quantity[248]	new[248]	_	_
41-7	4660-4670	relatively	quantity[248]	new[248]	_	_
41-8	4671-4676	large	quantity[248]	new[248]	_	_
41-9	4677-4683	sample	object|quantity[248]	new|new[248]	_	_
41-10	4684-4688	size	quantity[248]	new[248]	_	_
41-11	4689-4692	and	_	_	_	_
41-12	4693-4698	there	_	_	_	_
41-13	4699-4702	was	_	_	_	_
41-14	4703-4705	no	abstract[250]	new[250]	_	_
41-15	4706-4715	selection	abstract|abstract[250]	new|new[250]	_	_
41-16	4716-4720	bias	abstract[250]	new[250]	_	_
41-17	4721-4723	as	_	_	_	_
41-18	4724-4726	we	person	giv	ana	42-3
41-19	4727-4735	included	_	_	_	_
41-20	4736-4739	all	person[252]	giv[252]	_	_
41-21	4740-4743	the	person[252]	giv[252]	_	_
41-22	4744-4755	individuals	person[252]	giv[252]	_	_
41-23	4756-4759	who	_	_	_	_
41-24	4760-4764	were	_	_	_	_
41-25	4765-4775	enumerated	_	_	_	_
41-26	4776-4782	during	_	_	_	_
41-27	4783-4786	the	time[255]	giv[255]	_	_
41-28	4787-4792	study	abstract|time[255]	giv|giv[255]	coref	43-23[274_0]
41-29	4793-4802	reference	abstract|time[255]	new|giv[255]	_	_
41-30	4803-4809	period	time[255]	giv[255]	_	_
41-31	4810-4812	in	time[255]	giv[255]	_	_
41-32	4813-4815	60	time[255]|place[256]	giv[255]|new[256]	_	_
41-33	4816-4821	wards	time[255]|place[256]	giv[255]|new[256]	_	_
41-34	4822-4827	where	_	_	_	_
41-35	4828-4831	ACF	abstract	giv	_	_
41-36	4832-4834	is	_	_	_	_
41-37	4835-4846	implemented	_	_	_	_
41-38	4847-4848	.	_	_	_	_

#Text=Fourth , we used double data entry and validation using EpiData software and thus data entry errors were minimized .
42-1	4849-4855	Fourth	_	_	_	_
42-2	4856-4857	,	_	_	_	_
42-3	4858-4860	we	person	giv	ana	43-3
42-4	4861-4865	used	_	_	_	_
42-5	4866-4872	double	place[260]	new[260]	coref	42-16[0_260]
42-6	4873-4877	data	abstract|place[260]	new|new[260]	coref	42-15
42-7	4878-4883	entry	place[260]	new[260]	_	_
42-8	4884-4887	and	_	_	_	_
42-9	4888-4898	validation	abstract	new	_	_
42-10	4899-4904	using	_	_	_	_
42-11	4905-4912	EpiData	abstract|object[263]	new|new[263]	_	_
42-12	4913-4921	software	object[263]	new[263]	_	_
42-13	4922-4925	and	_	_	_	_
42-14	4926-4930	thus	abstract[266]	new[266]	_	_
42-15	4931-4935	data	abstract|abstract[266]	giv|new[266]	_	_
42-16	4936-4941	entry	place|abstract[266]	giv|new[266]	_	_
42-17	4942-4948	errors	abstract[266]	new[266]	_	_
42-18	4949-4953	were	_	_	_	_
42-19	4954-4963	minimized	_	_	_	_
42-20	4964-4965	.	_	_	_	_

#Text=Fifth , we adhered to STrengthening the Reporting of Observational studies in Epidemiology ( STROBE ) and COREQ guidelines for reporting the study ’s findings .
43-1	4966-4971	Fifth	_	_	_	_
43-2	4972-4973	,	_	_	_	_
43-3	4974-4976	we	person	giv	_	_
43-4	4977-4984	adhered	_	_	_	_
43-5	4985-4987	to	_	_	_	_
43-6	4988-5001	STrengthening	_	_	_	_
43-7	5002-5005	the	abstract[268]	new[268]	_	_
43-8	5006-5015	Reporting	abstract[268]	new[268]	_	_
43-9	5016-5018	of	abstract[268]	new[268]	_	_
43-10	5019-5032	Observational	abstract[268]|event[269]	new[268]|giv[269]	_	_
43-11	5033-5040	studies	abstract[268]|event[269]	new[268]|giv[269]	_	_
43-12	5041-5043	in	abstract[268]	new[268]	_	_
43-13	5044-5056	Epidemiology	abstract[268]|abstract	new[268]|new	appos	43-15
43-14	5057-5058	(	_	_	_	_
43-15	5059-5065	STROBE	abstract	giv	_	_
43-16	5066-5067	)	_	_	_	_
43-17	5068-5071	and	_	_	_	_
43-18	5072-5077	COREQ	organization|abstract[273]	new|new[273]	_	_
43-19	5078-5088	guidelines	abstract[273]	new[273]	_	_
43-20	5089-5092	for	_	_	_	_
43-21	5093-5102	reporting	_	_	_	_
43-22	5103-5106	the	abstract[275]	new[275]	_	_
43-23	5107-5112	study	abstract[274]|abstract[275]	giv[274]|new[275]	_	_
43-24	5113-5115	’s	abstract[274]|abstract[275]	giv[274]|new[275]	_	_
43-25	5116-5124	findings	abstract[275]	new[275]	_	_
43-26	5125-5126	.	_	_	_	_
